Nature Medicine
3, 632 - 638 (1997)
doi:10.1038/nm0697-632
Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domainGalina Selivanova1, 5, Violetta Iotsova2, 4, Ismail Okan1, Michael Fritsche3, Marika Ström1, Bernd Groner3, Roland C. Grafström2
& Klas G. Wiman1, 5
1Microbiology & Tumor Biology Center, and Karolinska Institute, S-71 77 Stockholm, Sweden
2Department of Environmental Medicine,Karolinska Institute, S-171 77 Stockholm, Sweden
3Institute for Experimental Cancer Research, Tumor Biology Center,Breisacherstrasse 117, D-79106 Freiburg,Germany
4Department of Molecular Biology,Bristol-Myers Squibb Pharmaceutical Research Institute,Princeton,New Jersey 08543-4000, USA
5Correspondence should be addressed to G.S. and K.G.W. We demonstrate here that synthetic 22-mer peptide 46, corresponding to the car boxy-terminal amino acid residues 361−382 of p53, can activate specific DNA binding of wild-type p53 in vitro and can restore the transcriptional transactivating function of at least some mutant p53 proteins in living cells. Introduction of peptide 46 in Saos-2 cells carrying a Tet-regulatable His-273 mutant p53 construct caused growth inhibition and apoptosis in the presence of mutant p53 but not in its absence, confirming that the effect of the peptide is mediated by reactivation of mutant p53. Moreover, peptide 46 caused apoptosis in mutant as well as wild-type p53-carrying human tumor cell lines of different origin, whereas p53 null tumor cells were not affected. These findings raise possibilities for developing drugs that restore the tumor suppressor function of mutant p53 proteins, thus selectively eliminating tumor cells.
REFERENCES
- Greenblatt, M.S., Bennet, W.P., Hollstein, M. & Harris, C.C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855−4878 (1994 | PubMed | ISI | ChemPort |
- Malkin, D., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasias. Science 250, 1233−1238 (1990 | PubMed | ISI | ChemPort |
- Donehower, L.A., et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356, 215−221 (1992 | Article | PubMed | ISI | ChemPort |
- Baker, S.J., Markowitz, E.R., Fearon, J.K., Willson, K.V. & Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912−915 (1990 | PubMed | ISI | ChemPort |
- Yonish-Rouach, E., et al. Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 353, 345−347 (1991 | Article |
- Kern, S.E., et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827−832 (1992 | PubMed | ISI | ChemPort |
- Cho, Y., Gorina, S., Jeffrey, P.D. & Pavletich, N.P. Crystal structure of a p53 tumor-suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 356−355 (1994 | ISI | ChemPort |
- Hupp, T.R.,& Lane, D.P. Allosteric activation of latent p53 tetramers. Curr. Biol 4, 865−875 (1994 | PubMed | ISI | ChemPort |
- Hupp, T.R., Sparks, A. & Lane, D.P. Small peptides activate the latent sequence-specific binding function of p53. Cell 83, 237−245 (1995 | Article | PubMed | ISI | ChemPort |
- Hupp, T.R., Meek, D.W., Midgley, C.A. & Lane, D.P. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21, 3167−3174 (1993 | PubMed | ISI | ChemPort |
- Halazonetis, T.D. & Kandil, A.N. Conformational shift propagate from oligomeriza-tion domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBOJ. 12, 5057−5064 (1993 | ChemPort |
- Niewolik, D., Vojtesek, B. & Kovarik, J. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10, 881−890 (1995 | PubMed | ISI | ChemPort |
- Abarzua, P., et al. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene 13, 2477−2482 (1996 | PubMed | ISI | ChemPort |
- Abarzua, P., LoSardo, J.E., Gubler, M.L. & Neri, A. Microinjecton of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer. Res 55, 3490−3494 (1995 | PubMed | ISI | ChemPort |
- Selivanova, G., et al. The single stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. Nucleic Acids Res. 24, 3560−3567 (1996 | Article | PubMed | ISI | ChemPort |
- Brugidou, J., Legrand, C., Mery, J. & Rable, A. The retro-inverso form of a home-obox-derived short peptide is rapidly internalized by cultured neurones: A new basis for an efficient intracellular delivery system. Biochem. Biophys. Res. Commun. 214, 685−693 (1995 | Article |
- Lowe, S.W., et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807−810 (1994 | PubMed | ISI | ChemPort |
- Wieczorek, A.M., Waterman, J.L.F., Waterman, M.J.F. & Halazonetis, T.D. Structure-based rescue of common tumor-derived p53 mutants. Nature Med 2, 1143−1146 (1996 | Article | PubMed | ISI | ChemPort |
- Symonds, H., et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703−711 (1994 | PubMed | ISI | ChemPort |
- Iotsova, V. & Stephelin, D. Antisense p53 provokes changes in HeLa cell growth and morphology. Eur. J. Cell Biol 68, 122−132 (1995 | PubMed | ISI | ChemPort |
- Gossen, M. & Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89, 5547−5551 (1992 | PubMed | ChemPort |
- Ramqvist, T., et al. Wild type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 8, 1495−1500 (1993 | PubMed | ISI | ChemPort |
- Okan, I., et al. The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 11, 1027−1031 (1995 | PubMed | ISI | ChemPort |
|
